Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with EGFR-TKIs plus Bevacizumab: A Case Report

Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with EGFR-TKIs plus Bevacizumab: A Case Report

Large cell neuroendocrine carcinoma (LCNEC) of the lung with epidermal growth factor receptor (EGFR) mutation is rare, and few cases have been treated with EGFR tyrosine kinase inhibitors (TKIs). We report the treatment of combined LCNEC with adenocarcinoma harboring an EGFR mutation with EGFR-TKIs...

Full description

Bibliographic Details
Main Authors: Satoshi Muto, Yuki Ozaki, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Yutaka Shio, Yuko Hashimoto, Hiroyuki Suzuki
Format: Article
Language:English
Published: Karger Publishers 2020-11-01
Series:Case Reports in Oncology
Subjects:
large cell neuroendocrine carcinoma
epidermal growth factor receptor mutation
tyrosine kinase inhibitors
bevacizumab
Online Access:https://www.karger.com/Article/FullText/511112

Similar Items

Similar Items